WuXi Biologics (Cayman) Inc
HKEX:2269

Watchlist Manager
WuXi Biologics (Cayman) Inc Logo
WuXi Biologics (Cayman) Inc
HKEX:2269
Watchlist
Price: 17.46 HKD 0.46% Market Closed
Market Cap: 72.5B HKD
Have any thoughts about
WuXi Biologics (Cayman) Inc?
Write Note

WuXi Biologics (Cayman) Inc
Investor Relations

WuXi Biologics (Cayman) Inc. emerged from the bustling arena of global pharmaceuticals as a beacon of innovation and flexibility in the biologics manufacturing space. Founded in 2010, this Chinese firm quickly established itself as a key player by offering a comprehensive suite of services that span the entire biologics development process. The company's strategy revolves around its "Follow-the-Molecule" business model, characterized by a symbiotic partnership with clients from the early stages of drug discovery through clinical development and all the way to commercial manufacturing. This approach ensures not only seamless integration across different development stages but also cultivates long-term relationships with clients, including startups and large pharmaceutical giants. Utilizing state-of-the-art technologies and an expansive network of manufacturing facilities around the globe, WuXi Biologics has positioned itself as an indispensable partner for firms looking to bring new biologics to market swiftly and efficiently.

The revenue model of WuXi Biologics hinges on its ability to offer flexible, customer-centric solutions in a highly demanding industry. Unlike traditional pharmaceutical companies that solely profit from drug sales, WuXi Biologics earns money by leveraging its Contract Development and Manufacturing Organization (CDMO) platform to provide end-to-end services. This includes process development, clinical trials, regulatory submissions, and commercial production. The company capitalizes on strategic partnerships and its burgeoning pipeline of projects, earning fees at each stage of the drug development cycle. By ensuring proprietary access to its advanced technologies and broad capabilities, WuXi Biologics not only supports its clients' needs but also fortifies its revenue streams via milestone payments, service fees, and long-term manufacturing contracts. Such a business model not only diversifies its income but also mitigates risks associated with drug development uncertainty, allowing the company to thrive in the competitive global healthcare market.

Show more

Earnings Calls

Show Transcript
Previous
Next
Loading

Management

Dr. Ge Li Ph.D.
Founder & Chairman
No Bio Available
Dr. Zhisheng Chen Ph.D.
CEO & Executive Director
No Bio Available
Dr. Weichang Zhou Ph.D.
Honorary President of Global Biologics Development, Senior Advisor to CEO & Non-Executive Director
No Bio Available
Mr. Ming Tu
CFO & Executive VP
No Bio Available
Lihua Yu M.B.A.
COO & Senior VP
No Bio Available
Dr. Sherry Gu Ph.D.
Chief Technology Officer and Executive VP of Global Biologics Development Department
No Bio Available
Dr. Jijie Gu Ph.D.
Chief Scientific Officer & President of Global Biologics Research
No Bio Available
Ms. Lina Fan Ph.D.
Senior VP & Head of Investor Relations
No Bio Available
He Wang
Chief Compliance Officer, Senior VP and Head of Global Compliance & Risk Management
No Bio Available
Ms. Li Xiong
VP & Head of Global Human Resources
No Bio Available

Contacts

Address
JIANGSU
Wuxi
No. 108, Meiliang Road, Mashan
Contacts